NEWS , Press release 2021.12.16 Rebirthel and Otsuka Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology

Rebirthel Co., Ltd. announces that it entered into an exclusive commercial licensing agreement with Otsuka Pharmaceutical Co., Ltd. for our technologies on CAR-T/TCR-T genetically engineered cell production using induced pluripotent stem (iPS) cells. The agreement covers multiple therapeutic areas worldwide. For details, please refer to the attached press release.

See the list of NEWS